ArticleAnnals of hematology2023

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.

Grzegorz S Nowakowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.